Table 1.
Characteristics of studies included in the InterLymph NHL Subtypes Project*
| Controls | Cases | Total | |
|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |
| Total | 17217 (98.2) | 324 (1.8) | 17541 |
| Study | |||
| North America | |||
| British Columbia | 845 (4.9) | 42 (13.0) | 887 |
| Mayo Clinic | 1314 (7.6) | 9 (2.8) | 1323 |
| NCI-SEER | 1055 (6.1) | 26 (8.0) | 1081 |
| Nebraska (newer) | 533 (3.1) | 7 (2.2) | 540 |
| UCSF1 | 2402 (14.0) | 47 (14.5) | 2449 |
| UCSF2 | 457 (2.7) | 54 (16.7) | 511 |
| University of Rochester | 139 (0.8) | 2 (0.6) | 141 |
| Yale | 717 (4.2) | 12 (3.7) | 729 |
| Europe | |||
| Epilymph | 2460 (14.3) | 38 (11.7) | 2498 |
| Italy multi-center | 1771 (10.3) | 25 (7.7) | 1796 |
| Italy (Aviano-Naples) | 504 (2.9) | 2 (0.6) | 506 |
| SCALE | 3187 (18.5) | 41 (12.7) | 3228 |
| United Kingdom | 1139 (6.6) | 15 (4.6) | 1154 |
| Australia | |||
| New South Wales | 694 (4.0) | 4 (1.2) | 698 |
| Region | |||
| North America | 7462 (43.3) | 199 (61.4) | 7661 |
| Northern Europe | 5820 (33.8) | 65 (20.1) | 5885 |
| Southern Europe | 3241 (18.8) | 56 (17.3) | 3297 |
| Australia | 694 (4.0) | 4 (1.2) | 698 |
| Design | |||
| Population-based | 13846 (80.4) | 280 (86.4) | 14126 |
| Hospital-based | 3371 (19.6) | 44 (13.6) | 3415 |
| Age, y | |||
| <30 | 993 (5.8) | 8 (2.5) | 1001 |
| 30–39 | 1686 (9.8) | 33 (10.2) | 1719 |
| 40–49 | 2543 (14.8) | 57 (17.6) | 2600 |
| 50–59 | 3940 (22.9) | 90 (27.8) | 4030 |
| 60–69 | 4848 (28.2) | 83 (25.6) | 4931 |
| 70–79 | 2949 (17.1) | 47 (14.5) | 2996 |
| ≥80 | 258 (1.5) | 6 (1.9) | 264 |
| Sex | |||
| Male | 9240 (53.7) | 184 (56.8) | 9424 |
| Female | 7977 (46.3) | 140 (43.2) | 8117 |
| Race | |||
| White, non-Hispanic | 15849 (92.1) | 271 (83.6) | 16120 |
| Black | 329 (1.9) | 19 (5.9) | 348 |
| Asian | 308 (1.8) | 22 (6.8) | 330 |
| Hispanic | 289 (1.7) | 7 (2.2) | 296 |
| Other/unknown/missing | 442 (2.6) | 5 (1.5) | 447 |
| Socioeconomic status | 6170 (35.8) | 117 (36.1) | 6287 |
| Medium | 5292 (30.7) | 94 (29.0) | 5386 |
| High | 5507 (32.0) | 109 (33.6) | 5616 |
| Other/missing | 248 (1.4) | 4 (1.2) | 252 |
| NHL classification | |||
| World Health Organization | 13044 (75.8) | 252 (77.8) | 13296 |
| Working Formulation | 4173 (24.2) | 72 (22.2) | 4245 |
* NHL = non-Hodgkin Lymphoma; NCI-SEER = National Cancer Institute Surveillance, Epidemiology, and End Results; SCALE = Scandinavian Lymphoma Etiology Study; UCSF = University of California San Francisco.